JPRN-UMIN000034253已完成未知
A Phase I/II study of mucosal immunotherapy using HPV-targeting Lactobacillus-based vaccine, IGMKK16E7, for treatment of HPV16-related high-grade squamous intraepithelial lesions: MILACLE study - MILACLE study
School of Medicine, Nihon University0 个研究点目标入组 164 人开始时间: 2019年1月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 164
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 45years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •(1) Immune compromised host or person who receive immunosuppressive therapy, (2) Patients who is suspected as invasive cancer, (3) Patients who has a previous history of hypersensitivity to Lactobacillus-content food/drug or milk, (4) Pregnant women or patients who expected to get pregnant, (5) Breast feeder mother.
研究者
相似试验
进行中（未招募）
不适用
A Phase I/II Study of Immunotherapy with Subcutaneous Administered Veltuzumab (hA20) in Patients with CD20+ Non-Hodgkin's Lymphoma or Chronic Lyphocytic LeukemiaEUCTR2008-000434-47-FRImmunomedics, Inc.46
未知
1 期
Phase I/II study of adoptive immunotherapy using cytotoxic T cells specific for minor histocompatibility antigen restricted to hematopoietic cells for patients with high-risk leukemia that relapsed following allogeneic hematopoietic stem cell transplantatio1) RAEB, CMML 2) AML or ALL in induction failure or beyond first remission 3) Ph/p190-positive ALL at any stage 4) imatinib-resistant CMJPRN-C000000162Aichi Cancer Center30
已完成
1 期
A phase I clinical study of immune cell therapy with MAGE-A4- or Survivin-specific Th1 cells for patients with refractory virulent tumorsRefractory cancer patients (MAGE-A4- or Survivin-expressing, non origin-limited) or the patients who refuse standard cancer therapyJPRN-UMIN000004828Department of General Surgery, Hokkaido University Graduated School of Medicine18
未知
1 期
Phase I/II study of adoptive immunotherapy using predetermined minor histocompatibility antigen-specific cytotoxic T cells for patients with high-risk leukemia that relapsed following allogeneic hematopoietic stem cell transplantation.1) RAEB, CMML 2) AML or ALL in induction failure or beyond first remission 3) Ph/p190-positive ALL at any stage 4) imatinib-resistant CMJPRN-C000000161Aichi Cancer Center30
招募中
2 期
Phase II Study of Local Therapy Combined with Immune Checkpoint Inhibitor for Oligo-Progressive disease during First-line Immunotherapy in non-small cell lung canceron-small cell lung cancerOligo-Progressive diseaseJPRN-jRCTs031220630Takahashi Kazuhisa60